ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Bortezomib

Also written as “bortezomib”, “VELCADE” and “VELCADE TM (bortezomib) for Injection”.

Its studies are mostly in Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Lymphoma, Mantle-Cell · Lymphoma, Follicular · Amyloidosis, led by 6 companies.

Drug pageBortezomib: every studyMany companies study it; this page follows only the 62 they lead. All 651 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 15, 201462 company-led studies, 7 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only285 open or runningphase 4since Oct 15, 2014Sep 13, 2005Feb 14, 2029phase 3 · NCT04923893
Takeda250 open or runningphase 4since Nov 18, 2005Oct 28, 2002none ahead
Oncotherapeuticsits history only40 open or runningphase 2since Apr 24, 2006Apr 19, 2006none ahead
AbbVieits history only32 open or runningphase 3since Nov 28, 2023Aug 19, 2016Dec 2027phase 3 · NCT06158841
AstraZenecaits history only10 open or runningphase 4since Aug 23, 2023Aug 23, 2023none ahead
Clinical Service, Chinaits history only10 open or runningphase 2since Mar 29, 2011Mar 29, 2011none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Oct 28, 2002.

  1. Aug 9, 2005Phase 1 study in NeoplasmsNCT00129207 · United States
  2. Nov 18, 2005Phase 4 study in Multiple MyelomaNCT00257114 · United States
  3. Jan 27, 2006Phase 2 study in NSCLCNCT00283634 · United States
  4. Mar 1, 2006Phase 2 study in AmyloidosisNCT00298766 · 70 enrolled · United States
  5. Apr 7, 2006Phase 3 study in Lymphoma, Non-HodgkinNCT00312845 · 676 enrolled · United States, Argentina, Australia and more
  6. Jun 22, 2006Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00343720 · Belgium
  7. Sep 14, 2007Phase 2 study in Multiple MyelomaNCT00531453 · 98 enrolled · Austria
  8. Jan 23, 2008Phase 1 study in Multiple MyelomaNCT00608907 · 61 enrolled · Israel, Italy, Poland and more
  9. Jan 28, 2008Phase 2 study in Ovarian NeoplasmsNCT00610792 · 91 enrolled · Italy, Switzerland
  10. Jul 11, 2008Phase 2 study in Lymphoma, FollicularNCT00715208 · 55 enrolled · United States, Puerto Rico
  11. Jul 23, 2008Phase 3 study in Lymphoma, Mantle-CellNCT00722137 · 487 enrolled · United States, Austria, Belgium and more
  12. Feb 24, 2009Phase 2 study in Lymphoma, FollicularNCT00850499 · 12 enrolled · France, Germany, Greece and more
  13. Jul 1, 2009Phase 2 study in Acromesomelic dysplasia, Maroteaux typeNCT00931918 · 206 enrolled · United States
  14. Dec 29, 2009Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT01040871 · 164 enrolled · Belgium

TargetBeta

“26S proteasome inhibitor; 26S proteasome inhibitor”ChEMBL 37, by rule

Other programs on the same 38 targets

ProgramCompanyFurthest phaseStudies
carfilzomibruleAmgenphase 438

Studies

All 25 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01040871Lymphoma, Large B-Cell, Diffuse · Belgium2CompletedJun 2012164
NCT00931918Acromesomelic dysplasia, Maroteaux type · United States2CompletedAug 2015206
NCT00850499Lymphoma, Follicular · France, Germany, Greece and more2TerminatedSep 201112
NCT00722137Lymphoma, Mantle-Cell · United States, Austria, Belgium and more3CompletedJan 1, 2014487
NCT00715208Lymphoma, Follicular · United States, Puerto Rico2CompletedFeb 201155
NCT00610792Ovarian Neoplasms · Italy, Switzerland2WithdrawnSep 200991
NCT00608907Multiple Myeloma · Israel, Italy, Poland and more1CompletedMar 201061
NCT00531453Multiple Myeloma · Austria2CompletedApr 200998
NCT00343720Carcinoma, Non-Small-Cell Lung · Belgium2CompletedOct 2007
NCT00312845Lymphoma, Non-Hodgkin · United States, Argentina, Australia and more3CompletedJun 2010676
NCT00298766Amyloidosis · United States2CompletedJul 200970
NCT00283634NSCLC · United States2TerminatedJul 2007
NCT00257114Multiple Myeloma · United States4CompletedMar 2007
NCT00129207Neoplasms · United States1CompletedSep 2006
NCT00117351Carcinoma, Non-Small-Cell Lung · United States2TerminatedJun 2007
NCT00111319Multiple Myeloma · United States3CompletedJul 2007
NCT00085696Lymphoma, B-Cell · United States2CompletedApr 200666
NCT00080405Multiple Myeloma1CompletedJun 200540
NCT00064636Advanced Non-Small Cell Lung Cancer1Terminated46
NCT00064610Prostatic Neoplasms · United States2CompletedDec 2004102
NCT00063726Multiple Myeloma · United States, Austria, Belgium and more3CompletedMay 2005600
NCT00063713Lymphoma, Mantle-Cell · United States2CompletedDec 2005152
NCT00051987Colorectal Neoplasms · United States2CompletedMar 2004175
NCT00051974Carcinoma, Non-Small-Cell Lung · United States2CompletedSep 2004155
NCT00048230Multiple Myeloma · United States, Austria, Belgium and more3CompletedJul 2004620

How it is read

Names in the registry

  • “Bortezomib”, 42 entries
  • “bortezomib”, 18 entries
  • “VELCADE”, 6 entries
  • “VELCADE TM (bortezomib) for Injection”, 2 entries
  • “VELCADE TM (bortezomib) for Injection, or PS-341”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.